Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity. (July 2017)

• Record Type: Journal Article
• Authors: Akinwande, Olaguoke; Shah, Veer; Mills, Abigail; Noda, Christopher; Weiner, Eric; Foltz, Gretchen; Saad, Nael
• Is Part Of: Hepatic oncology. Volume 4:Number 3(2017)
• Page Start: 75
• Page End: 81
• Publication Date: 2017-07
• Subjects: chemoembolization -- cholangiocarcinoma -- drug-eluting-beads -- efficacy -- radioembolization; Liver -- Cancer -- Periodicals; 616.99436005
• DOI: 10.2217/hep-2017-0005
• Languages: English
• ISSNs: 2045-0923

Abstract

Aim: Compare radioembolization (Y90) and chemoembolization (CE) for the treatment of unresectable intrahepatic cholangiocarcinoma (UICC).Materials & methods: Institutional Review Board-approved, retrospective search was performed. Forty patients with UICC were treated with either Y90 (n = 25, 39 treatments) or CE (n = 15, 35 treatments). Comparative analysis was performed using Student's t and fisher-exact tests. Multivariable-logistic regression was also performed.Results: Median ages were 60 and 64 years for CE and Y90 groups, respectively (p = 0.798). Patient variables including age, Eastern Cooperative Oncology Group score, tumor burden, extra-hepatic disease, prior chemotherapy and prior surgery were similar between groups. Adverse events were similar in both groups (CE 20%, Y90 26%; p > 0.9). Overall response rate (CE 6%, Y90 4%; p > 0.9) and disease control rate (CE 46%, Y90 48%; p > 0.9) were statistically similar. Multilogistic regression did not identify any variables that correlated with disease control rate, including Eastern Cooperative Oncology Group score and tumor burden.Conclusion: Our observation shows that CE and Y90 display similar toxicity and disease control in the treatment of UICC.